| abstract |
Provided are a substituted pyrrolopyrimidine compound and composition containing said compound, and an application thereof. Specifically disclosed is the pyrrolopyrimidine compound represented by formula (I), or a pharmaceutical composition of its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate, or solvate. The compound may be used as a cyclin-dependent kinase (CDK) inhibitor, and thus is suitable for use as a drug to treat CDK-related diseases (such as breast cancer). |